[go: up one dir, main page]

MX2018007479A - Anticuerpos variantes para conjugacion especifica de sitio. - Google Patents

Anticuerpos variantes para conjugacion especifica de sitio.

Info

Publication number
MX2018007479A
MX2018007479A MX2018007479A MX2018007479A MX2018007479A MX 2018007479 A MX2018007479 A MX 2018007479A MX 2018007479 A MX2018007479 A MX 2018007479A MX 2018007479 A MX2018007479 A MX 2018007479A MX 2018007479 A MX2018007479 A MX 2018007479A
Authority
MX
Mexico
Prior art keywords
site
variant antibodies
specific conjugation
cysteine
antibodies
Prior art date
Application number
MX2018007479A
Other languages
English (en)
Inventor
Andersen Henrik
O Sheppard Paul
Rajpal Arvind
Shao Xiang
Rao-Naik Chetana
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2018007479A publication Critical patent/MX2018007479A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anticuerpos variantes que tienen sustituciones de cisteína en posiciones seleccionadas en la región Fc se pueden conjugar a través del grupo tiol de la cisteína sustituida.
MX2018007479A 2015-12-21 2016-12-20 Anticuerpos variantes para conjugacion especifica de sitio. MX2018007479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562270245P 2015-12-21 2015-12-21
PCT/US2016/067663 WO2017112624A1 (en) 2015-12-21 2016-12-20 Variant antibodies for site-specific conjugation

Publications (1)

Publication Number Publication Date
MX2018007479A true MX2018007479A (es) 2018-08-01

Family

ID=57944491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007479A MX2018007479A (es) 2015-12-21 2016-12-20 Anticuerpos variantes para conjugacion especifica de sitio.

Country Status (13)

Country Link
US (1) US20180362619A1 (es)
EP (1) EP3394096A1 (es)
JP (1) JP2019505575A (es)
KR (1) KR20180089433A (es)
CN (1) CN108431034A (es)
AU (1) AU2016377371A1 (es)
BR (1) BR112018012524A2 (es)
CA (1) CA3008678A1 (es)
EA (1) EA201891482A1 (es)
IL (1) IL260049A (es)
MX (1) MX2018007479A (es)
SG (1) SG11201805150QA (es)
WO (1) WO2017112624A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278461A (zh) 2017-08-16 2020-06-12 百时美施贵宝公司 可前药化抗体、其前药以及使用和制备方法
WO2019068756A1 (en) 2017-10-03 2019-04-11 Merck Patent Gmbh MODIFIED CYSTEINE MOLECULES BINDING TO ANTIGEN
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126250A (en) 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JPH11513391A (ja) 1995-10-03 1999-11-16 ザ スクリップス リサーチ インスティテュート Ｃｃ−１０６５ 及びズオカーマイシンのｃｂｉ 類縁体
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
JP4118462B2 (ja) 1999-07-19 2008-07-16 株式会社リコー 携帯電子機器
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
KR100668538B1 (ko) 2002-01-09 2007-01-16 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
KR101215218B1 (ko) 2003-07-22 2012-12-26 바이엘 파마 악티엔게젤샤프트 Ｒｇ１ 항체 및 그의 용도
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
HUE025328T2 (en) 2003-12-10 2016-03-29 Squibb & Sons Llc IP-10 antibodies and their use
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7778814B2 (en) 2004-03-30 2010-08-17 Siemens Aktiengesellschaft Method and device for simulating an automation system
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
EP2325206B1 (en) 2004-11-12 2014-03-19 Xencor, Inc. Fc variants with altered binding to fcrn
CN101160324B (zh) 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
CN101124249B (zh) 2005-02-18 2011-06-29 米德列斯公司 抗前列腺特异性膜抗原（psma）的人单克隆抗体
US20100104564A1 (en) 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
MX2007013924A (es) 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
WO2007038868A2 (en) 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
CN103204931B (zh) 2005-12-08 2016-08-03 米德列斯公司 抗岩藻糖基-gm1的人单克隆抗体及使用抗岩藻糖基-gm1抗体的方法
PT1957539E (pt) 2005-12-08 2013-06-25 Medarex Inc Anticorpos monoclonais humanos para a proteína tirosinacinase 7 (ptk7) e sua utilização
US8609816B2 (en) 2005-12-08 2013-12-17 Medarex, L.L.C. Human monoclonal antibodies to O8E
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
PE20080316A1 (es) 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
AR062448A1 (es) 2006-05-25 2008-11-12 Endocyte Inc Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
WO2008066583A2 (en) 2006-06-29 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Cell-free synthesis of proteins containing unnatural amino acids
EP2064316B1 (en) 2006-09-08 2012-01-25 Ambrx, Inc. Site specific incorporation of non-natural amino acids by vertebrate cells
BRPI0718197A2 (pt) 2006-10-02 2014-09-30 Medarex Inc Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-cxcr4, para modular a atividade do cxcr4 em uma célula, e para estimular a mobilização de células tronco cd34+ da medula óssea para o sangue periférico em um indivíduo.
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
CN101626782B (zh) 2006-12-01 2013-03-27 梅达雷克斯公司 结合cd22的人抗体及其用途
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
MX2010000537A (es) 2007-07-17 2010-03-25 Medarex Inc Anticuerpos monoclonales contra glipicano-3.
BRPI0816014A8 (pt) 2007-10-01 2018-06-19 Bristol Myers Squibb Co anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
AU2011239522B2 (en) 2010-04-15 2014-10-23 Medimmune Limited Targeted pyrrolobenzodiazapine conjugates
JP5875083B2 (ja) 2010-04-15 2016-03-02 メディミューン リミテッド 増殖性疾患治療用ピロロベンゾジアゼピン
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
JP6099336B2 (ja) 2011-09-14 2017-03-22 株式会社半導体エネルギー研究所 発光装置
AU2012311505B2 (en) 2011-09-20 2016-09-29 Medimmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
EP2794653B1 (en) 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
DK2814829T3 (en) 2012-02-13 2017-03-20 Bristol Myers Squibb Co RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES
WO2014004639A1 (en) * 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
ES2874493T3 (es) 2013-02-08 2021-11-05 Novartis Ag Sitios específicos para modificar anticuerpos para generar inmunoconjugados
LT2956173T (lt) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
JP6474404B2 (ja) 2013-08-14 2019-02-27 ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用
WO2015138615A2 (en) 2014-03-12 2015-09-17 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
RU2711485C2 (ru) 2014-04-11 2020-01-17 МЕДИММЬЮН, ЭлЭлСи Конъюгированные соединения, содержащие сконструированные с цистеином антитела
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
WO2016054315A1 (en) 2014-10-01 2016-04-07 Medimmune, Llc Method of conjugating a polypeptide

Also Published As

Publication number Publication date
US20180362619A1 (en) 2018-12-20
JP2019505575A (ja) 2019-02-28
KR20180089433A (ko) 2018-08-08
IL260049A (en) 2018-07-31
EP3394096A1 (en) 2018-10-31
EA201891482A1 (ru) 2018-12-28
BR112018012524A2 (pt) 2018-12-11
CN108431034A (zh) 2018-08-21
AU2016377371A1 (en) 2018-08-09
SG11201805150QA (en) 2018-07-30
CA3008678A1 (en) 2017-06-29
WO2017112624A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
PH12018501042A1 (en) Antibodies and antibody fragments for site-specific conjugation
PH12019500627A1 (en) Affinity-oligonucleotide conjugates and uses thereof
MY191169A (en) Anti-fcrh5 antibodies
PH12018500815A1 (en) Antibody conjugates comprising toll-like receptor agonist
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
MX391989B (es) Conjugados de amatoxina y anticuerpos.
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
IL267478A (en) Antibody-drug conjugates for hematopoietic stem cell ablation
MX2019007021A (es) Anticuerpos il-11ra.
PH12016501411B1 (en) Bifunctional cytotoxic agents
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
PH12016501680B1 (en) Anti-egfrviii antibodies and uses thereof
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MA40459A (fr) Anticorps anti-age pour le traitement de l'inflammation et de troubles auto-immuns
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX2018007479A (es) Anticuerpos variantes para conjugacion especifica de sitio.
IL279440A (en) Antibody-drug conjugates for hematopoietic stem cell ablation
EA201591709A1 (ru) 5-бром-индирубины
BR112016007816A2 (pt) composições peptídicas inovadoras
HK40019179A (en) Cysteine mutated antibodies for conjugation
HK40012760A (en) Antibody drug conjugates for ablating hematopoietic stem cells
UA90689U (uk) Комплексний протипаразитарний препарат "лактоверм"